m+Medelevator.RU
← Поиск публикаций
Current topics in microbiology and immunology · 2026

15-Hydroxyprostaglandin Dehydrogenase: A Key Metabolic Enzyme for Prostaglandins, 12-Hydroxyheptadecatrienoic Acid, and Resolvins.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Tai Hsin-Hsiung, Zhu Haining, Chiang Nan

Аннотация

The 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a key prostaglandin catabolic enzyme. It is well known that 15-PGDH catalyzes the oxidation of prostaglandin E2 (PGE2) to form 15-oxo-PGE2 that is biologically inactive. The catalytic sites of 15-PGDH have been revealed using site-directed mutagenesis, homology modeling, molecular docking, and molecular dynamics simulation. 15-PGDH also catalyzes the oxidation of 12S-hydroxyheptadecatrienoic acid (12-HHT) to generate the 12-keto-heptadecatrienoic acid (12-KHT). Substrate specificity studies were carried out using a steady-state kinetic approach with highly purified 15-PGDH, and 12-HHT gave the highest affinity and efficiency among all 15-PGDH substrates including PGE2 and PGF2α. 12-HHT was shown to be a potent ligand for leukotriene B4 receptor 2 (BLT2), and the 12-HHT-BLT2 axis is likely to play an important role in wound healing and tissue regeneration. Unlike 15-oxo-PGE2, 12-KHT remains bioactive with an affinity to BLT2 comparable to that of 12-HHT. In addition to prostaglandins and 12-HHT, the pro-resolving mediators, including lipoxins and resolvins, are also sensitive to rapid inactivation via dehydrogenation by 15-PGDH. Screening of a list of natural products, anti-inflammatories and cardiovascular drugs, several 15-PGDH inhibitors have been identified, which have high potency in promoting wound healing and regeneration, likely via the preservation of the anti-inflammatory and pro-resolving substrates of 15-PGDH, including 12-HHT, lipoxins, and resolvins. The detailed studies on 15-PGDH substrate specificity provide molecular basis for designing longer-acting stable analogs of the substrates or high-affinity inhibitors that block 15-PGDH enzymatic activity. These stable analogs and inhibitors could have therapeutic potential in limiting inflammatory and neurodegenerative diseases, as well as stimulating wound healing and regeneration, leading to healthy aging.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты